Le Lézard3h
Theratechnologies Receives FDA Approval for EGRIFTA WRtm (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a commercial-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
Le Lézard3h
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced abstracts detailing multiple preclinical programs have been accepted ...
TMCnet4h
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile VANCOUVER, British Columbia, March 25, 2025 (GLOBE ...
Fierce Pharma6h
GSK ushers in new UTI antibiotic with FDA nod for first-in-class Blujepa
GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...
FDA approves a new kind of oral antibiotic to treat urinary tract infections
The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, ...
FDA approves Tremfya for active Crohn's disease in adults
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025
ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta. Read why ADCT stock is rated as a ...
FDA approves new drug to treat heart conditions
The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...
BioSpace1d
AbbVie Lawsuit Alleges That Partner Genmab “Misappropriated” Trade Secrets
AbbVie claims that Genmab divulged key trade secrets to support the development of ProfoundBio’s investigational ...
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...